Telaprevir and boceprevir show high rate of serious side-effects in hepatitis C patients with urgent need of treatment

Keith Alcorn, Michael Carter
Published: 20 April 2012

A real-world study of new hepatitis C protease inhibitors in the group of patients who have been told they should not wait for newer, experimental antivirals has shown a much higher rate of serious adverse events and treatment discontinuations than in clinical trials, Dr Christophe Hézode reported on behalf of the French Compassionate Use of Protease Inhibitors in Cirrhotics cohort study at the 2012 International Liver Congress in Barcelona on Thursday.

However, rates of virologic response after 16 weeks of treatment were high in this group of patients, who had previously relapsed or failed to respond to pegylated interferon and ribavirin.

The programme and cohort study were established prior to the licensing of telaprevir (Incivo/Incivek) and boceprevir (Victrelis) in Europe, in order to provide early access to the new drugs in patients with hepatitis C judged to be in urgent need of treatment. Under French law, experimental drugs may be made available prior to licensing to patients with urgent clinical needs, if data on safety are collected.

The cohort study sought to evaluate outcomes in people who received the drugs, and in particular to evaluate the tolerability and efficacy of the new drugs in people with hepatitis C mono-infection and compensated cirrhosis with a previous history of non-response or relapse after standard treatment with pegylated interferon and ribavirin.

Early access was provided to telaprevir or boceprevir for 655 patients at 55 hospitals in France; 455 were eligible for inclusion in the cirrhosis analysis (296 telaprevir, 149 boceprevir).

The telaprevir regimen consisted of twelve weeks of telaprevir in combination with standard hepatitis C treatment, followed by a further 36 weeks of pegylated interferon and ribavirin. The boceprevir regimen comprised four weeks of lead-in treatment with pegylated interferon and ribavirin, followed by 44 weeks of boceprevir with pegylated interferon and ribavirin. This study did not report on sustained virologic response after completion of treatment and efficacy and adverse event data over the first 16 weeks of treatment. However, week 16 on-treatment virologic response data showed that 86% (177 of 205 patients) of telaprevir-treated patients and 71% (89 of 126) of boceprevir-treated patients had undetectable hepatitis C viral load.

There was no randomisation, which precluded any comparison between the safety profiles of the two drugs.

Most of the patients were male and their mean age was 57 years.

Just under half (48.6%) of patients receiving telaprevir experienced a serious adverse event as did 38% of those treated with boceprevir. This high prevalence of serious side-effects contrasted to the rates of between 9 and 14% observed in the phase III studies which led to the licensing of the drugs. 14.5% of the telaprevir-treated patients and 7% of the boceprevir-treated patients discontinued treatment as a result of serious adverse events.

“The safety profile of telaprevir or boceprevir with pegylated interferon/ribavirin in cirrhotic patients was poor,” comment the investigators.

Grade 2 anaemia (definted as 8.0-10.0 g/dl) developed in 19.6% of telaprevir-treated patients and 22% of individuals receiving boceprevir-based therapy. Grade 3-4 anaemia (< 8.0 g/dl) was observed in 10% of those taking telaprevir and 10% of patients treated with boceprevir.

EPO therapy for anaemia was provided to 56% of telaprevir patients and 66% of boceprevir patients. A fifth of people taking telaprevir and 10% of those treated with boceprevir required a blood transfusion.

Serious (grade 3-4, < 50,000/mm3) thrombopenia was also common. It developed in 13 and 7% of telaprevir and boceprevir-treated patients respectively. Neutropenia grade 3-4 ( < 1000/mm3) was observed in 5% of telaprevir and boceprevir-treated patients.

Although serious infections were rare (1 to 2%), a large proportion of patients developed other grade 3-4 adverse events such as rash, pruritis and hepatic decompensation (53% telaprevir; 32% boceprevir).

“These data strongly suggest that triple therapy must be administered cautiously with intensive safety monitoring in…patients [with cirrhosis],” conclude the investigators.


Hezode C et al. Safety of telaprevir and boceprevir in combination with preginterferon alfa/ribavirin, in cirrhotic non responders. First results of the French early access program (ANRS CO20-CUPIC).  International Liver Congress 2012.

Hepatitis information

For more information on hepatitis visit

Infohep is a project we're working on with the World Hepatitis Alliance and the European Liver Patients Association.

Visit >
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.